Literature DB >> 11113414

Clinical impact of borderline and undiagnosed diabetes mellitus in patients with coronary artery disease.

A Tenenbaum1, M Motro, E Z Fisman, V Boyko, L Mandelzweig, H Reicher-Reiss, E Graff, D Brunner, S Behar.   

Abstract

The present study was aimed to evaluate the prevalence and prognostic significance of unrecognized and newly defined borderline diabetes (with fasting blood sugar 126 to 139 mg/dl) by the American Diabetes Association criteria in coronary patients over a 7.7-year follow-up. Both undiagnosed and newly diagnosed borderline diabetes were associated with an unfavorable metabolic profile. The mortality of the borderline diabetics tended to be higher than in their nondiabetic counterparts. but this tendency did not reach statistical significance. A significant excess in long-term mortality was observed among the undiagnosed diabetes group.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11113414     DOI: 10.1016/s0002-9149(00)01244-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Age- and gender-specific awareness, treatment, and control of cardiovascular risk factors and subclinical vascular lesions in a founder population: the SardiNIA Study.

Authors:  A Scuteri; S S Najjar; M Orru'; G Albai; J Strait; K V Tarasov; M G Piras; A Cao; D Schlessinger; M Uda; E G Lakatta
Journal:  Nutr Metab Cardiovasc Dis       Date:  2009-03-25       Impact factor: 4.222

2.  Seven-year mortality in heart failure patients with undiagnosed diabetes: an observational study.

Authors:  Juana A Flores-Le Roux; Josep Comin; Juan Pedro-Botet; David Benaiges; Jaume Puig-de Dou; Juan J Chillarón; Alberto Goday; Jordi Bruguera; Juan F Cano-Perez
Journal:  Cardiovasc Diabetol       Date:  2011-05-14       Impact factor: 9.951

3.  Usefulness of electronic databases for the detection of unrecognized diabetic patients.

Authors:  Shlomo Vinker; Yaacov Fogelman; Asher Elhayany; Sasson Nakar; Ernesto Kahan
Journal:  Cardiovasc Diabetol       Date:  2003-11-14       Impact factor: 9.951

Review 4.  A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.

Authors:  Enrique Z Fisman; Alexander Tenenbaum
Journal:  Cardiovasc Diabetol       Date:  2009-07-20       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.